Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alkem Laboratories Ltd

http://alkemlabs.com/

Latest From Alkem Laboratories Ltd

India Biosimilar Cetuximab Go-Ahead: Merck KGaA Wants Data In Public Domain

Merck KGaA calls for data on Indian firm Enzene’s biosimilar cetuximab to be made available in the public domain, citing the Helsinki Declaration.

India Commercial

Pfizer Ibrance India Case: ‘Willful Contempt’ Lands Local Firm In Soup

An Indian court has directed a local firm to pay a specified sum to Pfizer for contempt of court in a case pertaining to its patent on palbociclib, failing which its senior executive could face a two-week prison term.

India Commercial

Big Pharma Restructures Commercial Teams In India

More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.

India Commercial

US Pricing Pressure Spotlights Regulatory Compliance As Key To Indian Companies’ Performance

While generic drug prices continued to erode in the US during the second quarter of FY23, compliance will be key to the performance of Indian firms such as Torrent and Jubilant through the rest of the year. The US FDA has issued multiple observations in 2022, but an import alert for Glenmark’s Baddi unit is the harshest so far.

Strategy Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register